CI heads into its Q1 2026 earnings today with the Street broadly bullish but divided on the one metric that matters most: whether Evernorth's margin compression is manageable or structural.
The bull-versus-bear divide is unusually sharp and unusually specific. Bears point to a steep drop in Evernorth Adjusted Operating Income — from roughly $3.5 billion in 2025 to an anticipated $2.75 billion in 2026, a hit of around $758 million. The culprit is a transition to a rebate-free pharmacy benefit management model, which alone could strip $500–$600 million from 2026 earnings. Bulls counter that the stop-loss margin recovery in the healthcare segment is on track, with 100 basis points of recapture expected by 2027 — mostly in this year — and that Evernorth's patient-satisfaction and cost-reduction story remains intact. The consensus leans constructive: analysts carry a buy rating with a mean target of $336, implying roughly 16% upside from current levels at $290.58. Jefferies trimmed its target modestly to $330 on April 20 while holding its buy — the kind of fine-tuning rather than capitulation that characterises a still-supportive but increasingly cautious analyst community.
The positioning data tells a relaxed story. Short interest is light at 2.4% of the free float and has drifted lower all month, down nearly 2% over four weeks. Borrow availability is wide open — the lending pool is barely tapped. Cost to borrow hovers around 0.38%, essentially free. None of that signals a community of investors making aggressive directional bets against the name. The options market echoes the same tone: the put/call ratio at 0.53 is slightly above its 20-day average of 0.51 but well within normal bounds, and the z-score of 0.75 shows no unusual hedging demand heading into the print.
The stock's recovery adds context. CI has climbed more than 12% over the past month after a weaker stretch earlier in the year, closing at $290.58. Peers have largely moved in tandem — ELV added nearly 9% on the week and CVS gained more than 5%. The managed care and PBM complex has broadly rebounded. BlackRock added over a million shares in Q1, and most of the major passive holders nudged positions slightly higher. The insider picture is less constructive: CEO David Cordani and the President/COO both sold shares in late February, though the amounts were modest relative to total holdings and may reflect routine compensation-linked activity.
The Q1 print is therefore a direct test of whether Cigna's Evernorth margin trajectory is unfolding as management guided — or whether the rebate-model transition and biosimilar adoption headwinds are arriving faster and harder than the Street has priced in.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
